CA2472240A1 - Tibolone in the treatment of complaints associated with the administration of drugs which prevent the synthesis of endogenous estrogen - Google Patents

Tibolone in the treatment of complaints associated with the administration of drugs which prevent the synthesis of endogenous estrogen Download PDF

Info

Publication number
CA2472240A1
CA2472240A1 CA002472240A CA2472240A CA2472240A1 CA 2472240 A1 CA2472240 A1 CA 2472240A1 CA 002472240 A CA002472240 A CA 002472240A CA 2472240 A CA2472240 A CA 2472240A CA 2472240 A1 CA2472240 A1 CA 2472240A1
Authority
CA
Canada
Prior art keywords
estrogen
complaints
treatment
tibolone
synthesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002472240A
Other languages
English (en)
French (fr)
Inventor
Helenius Jan Kloosterboer
Nigel Bundred
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon NV
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2472240A1 publication Critical patent/CA2472240A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
CA002472240A 2002-01-22 2003-01-16 Tibolone in the treatment of complaints associated with the administration of drugs which prevent the synthesis of endogenous estrogen Abandoned CA2472240A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02075235 2002-01-22
EP02075235.8 2002-01-22
PCT/EP2003/000373 WO2003061665A1 (en) 2002-01-22 2003-01-16 Tibolone in the treatment of complaints associated with the administration of drugs which prevent the synthesis of endogenous estrogen

Publications (1)

Publication Number Publication Date
CA2472240A1 true CA2472240A1 (en) 2003-07-31

Family

ID=27589110

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002472240A Abandoned CA2472240A1 (en) 2002-01-22 2003-01-16 Tibolone in the treatment of complaints associated with the administration of drugs which prevent the synthesis of endogenous estrogen

Country Status (16)

Country Link
US (1) US20050124592A1 (enExample)
EP (1) EP1469861A1 (enExample)
JP (1) JP2005518412A (enExample)
KR (1) KR20040073572A (enExample)
CN (1) CN1620298A (enExample)
BR (1) BR0306789A (enExample)
CA (1) CA2472240A1 (enExample)
EC (1) ECSP045179A (enExample)
HR (1) HRP20040635A2 (enExample)
IL (1) IL162769A0 (enExample)
IS (1) IS7338A (enExample)
MX (1) MXPA04007071A (enExample)
PL (1) PL371181A1 (enExample)
RU (1) RU2004125594A (enExample)
WO (1) WO2003061665A1 (enExample)
ZA (1) ZA200405262B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0302572D0 (en) 2003-02-05 2003-03-12 Astrazeneca Ab Method of treatment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE63051B1 (en) * 1989-03-18 1995-03-22 Akzo Nv Pharmaceutical composition which contains a pharmaceutically suitable carrier and the compound having the structure (7alpha, 17alpha)-17-Hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn- 3-one
AU671706B2 (en) * 1993-03-05 1996-09-05 Akzo N.V. Use of a Pregnane Derivative
JP2002522425A (ja) * 1998-08-07 2002-07-23 カイロン コーポレイション エストロゲンレセプターモジュレーターとしての置換イソオキサゾール

Also Published As

Publication number Publication date
JP2005518412A (ja) 2005-06-23
RU2004125594A (ru) 2005-03-10
IS7338A (is) 2004-06-28
IL162769A0 (en) 2005-11-20
CN1620298A (zh) 2005-05-25
WO2003061665A1 (en) 2003-07-31
EP1469861A1 (en) 2004-10-27
US20050124592A1 (en) 2005-06-09
BR0306789A (pt) 2004-12-28
ECSP045179A (es) 2004-08-27
ZA200405262B (en) 2005-08-31
PL371181A1 (en) 2005-06-13
KR20040073572A (ko) 2004-08-19
HRP20040635A2 (en) 2004-10-31
MXPA04007071A (es) 2004-10-29

Similar Documents

Publication Publication Date Title
CA2394165A1 (en) Drospirenone for hormone replacement therapy
EP0354921A1 (en) COMPOSITIONS AND METHOD FOR CONTRACEPTION AND PREVENTION OF CHEST CANCER.
US20050222100A1 (en) Treatment of post-menopausal complaints in breast cancer patients comprising tibolone and a serm
TWI354556B (en) Use of a combination of an aromatase inhibitor,a p
EP1406634A1 (en) Combination of drospirenone and an estrogen sulphamate for hrt
WO2001049294A1 (en) Product for treating gynecomastia
SK11902002A3 (sk) Použitie exemestanu na prípravu liečiva
Moguilewsky et al. Pharmacological and clinical studies of the antiandrogen Anandron
US20050124592A1 (en) Tibolone in the treatment of complaints associated with the administration of drugs which prevent the synthesis of endogenous estrogen
AU2003236806A1 (en) Tibolone in the treatment of complaints associated with the administration of drugs which prevent the synthesis of endogenous estrogen
CA2306110A1 (en) Therapeutic agent of uterine leiomyoma, containing dienogest as effective ingredient
CA2248841C (en) Sequential oestrogen/progesterone antagonist combination for hormone replacement therapy
AU2003206424B2 (en) Sequential estrogen/progesterone antagonist combination for hormone replacement therapy
HK1113546A (en) Composition comprising a combination of an aromatase inhibitor, a progestin and an estrogen, and its use for the treatment of endometriosis
HK1082918B (en) Use of a combination of an aromatase inhibitor, a progestin and an oestrogen for the treatment of endometriosis

Legal Events

Date Code Title Description
FZDE Discontinued